العلاج الجهازي خط أول لسرطان الغدة الدرقية الجُريبي المتقدم أو المنتشر المقاوم لليود المشع

References

• Lenvatinib and sorafenib should be considered the standard first-line systemic therapy for RAI-refractory DTC [I, A; ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.1 scores: 3 for lenvatinib, 2 for sorafenib].
• In the DECISION trial, 417 patients were randomised (1 : 1) to treatment with sorafenib or placebo, with crossover permitted at disease progression.
• The results of chemotherapy administration (e.g. doxorubicin) in RAI-refractory DTC are disappointing; therefore, it is not recommended unless MKI therapy is contraindicated.
• Reductions in serum Tg are expected in responders, but clinical decisions cannot be based on this parameter alone.
• The imaging assessment should be repeated every 3–12 weeks during treatment.